MCID: BRS049
MIFTS: 51

Breast Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 44 15
Carcinoma in Situ of Breast 12 33
Non-Infiltrating Carcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD9CM 35 233.0
MeSH 44 D000071960
ICD10 33 D05 D05.9
UMLS 72 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as carcinoma in situ of breast, is related to lobular neoplasia and comedo carcinoma. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Medroxyprogesterone acetate and Oxybutynin have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 lobular neoplasia 32.9 ESR1 ERBB2 BRCA1
2 comedo carcinoma 32.6 ESR1 ERBB2
3 ductal carcinoma in situ 30.5 TP53 PGR KRT5 ESR1 ERBB2 BRCA2
4 pre-eclampsia 29.4 VEGFA KDR IL6 FLT1
5 in situ carcinoma 29.4 TP53 PGR KRT5 ESR1 ERBB2 BRCA1
6 mammary paget's disease 29.2 PGR ESR1 ERBB2
7 breast fibroadenoma 29.2 PGR ESR1 ERBB2
8 tubular adenocarcinoma 29.2 PGR ESR1 ERBB2
9 breast ductal carcinoma 28.7 VEGFC TP53 PGR MET ESR1 ERBB2
10 female breast cancer 28.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
11 ovarian cancer 27.1 VEGFA TP53 PGR MMP2 KDR ESR1
12 breast disease 26.7 VEGFA TP53 PGR KRT5 KRT19 ESR1
13 breast cancer 24.0 VEGFC VEGFA TP53 PGR MMP2 MET
14 breast apocrine carcinoma in situ 12.0
15 hereditary site-specific ovarian cancer syndrome 10.8 BRCA2 BRCA1
16 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
17 tuberculous salpingitis 10.7 ERBB2 BRCA2 BRCA1
18 fallopian tube adenocarcinoma 10.7 ERBB2 BRCA2 BRCA1
19 uterine corpus serous adenocarcinoma 10.6 TP53 ERBB2 BRCA1
20 mutagen sensitivity 10.6 TP53 BRCA2 BRCA1
21 hemifacial spasm 10.6 VEGFA FLT4
22 vulvar intraepithelial neoplasia 10.6 TP53 MMP2
23 hereditary breast ovarian cancer syndrome 10.5 TP53 BRCA2 BRCA1
24 male reproductive system disease 10.5 VEGFA TP53 IL6
25 li-fraumeni syndrome 10.5 TP53 BRCA2 BRCA1
26 grade iii astrocytoma 10.5 VEGFA TP53 MMP2
27 tongue disease 10.5 VEGFC TP53 MMP2
28 gorham's disease 10.4 VEGFC FLT4
29 microcystic meningioma 10.4 VEGFA MMP2 FLT1
30 connective tissue cancer 10.4 VEGFA TP53 FGF2
31 infiltrating angiolipoma 10.4 VEGFC VEGFA
32 oral cavity cancer 10.4 VEGFA TP53 ERBB2
33 lymphangiosarcoma 10.4 VEGFC VEGFA FLT4
34 breast cystic hypersecretory carcinoma 10.4 KRT5 ERBB2
35 differentiated thyroid carcinoma 10.4 VEGFA TP53 MET
36 tongue cancer 10.4 VEGFC TP53 MMP2
37 gliosarcoma 10.4 TP53 MMP2 FGFR1
38 skin melanoma 10.4 TP53 MMP2 FGF2
39 renal cell carcinoma, papillary, 1 10.4 TP53 MET ERBB2
40 primary effusion lymphoma 10.4 VEGFA MET IL6
41 stomach disease 10.4 VEGFA TP53 MET ERBB2
42 malignant spiradenoma 10.3 TP53 KRT5
43 peritoneum cancer 10.3 KRT5 BRCA2 BRCA1
44 poems syndrome 10.3 VEGFA IL6 FGF2
45 breast squamous cell carcinoma 10.3 TP53 KRT5 ERBB2
46 diabetic macular edema 10.3 VEGFA IL6 FGF2
47 pericardial effusion 10.3 VEGFA IL6 FGF2
48 tonsil cancer 10.3 TP53 KRT5 ERBB2
49 congenital lymphedema 10.3 VEGFC FLT4
50 intestinal disease 10.3 VEGFA TP53 IL6

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.68 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.68 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.68 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.68 ESR1 KDR
5 Decreased viability GR00301-A 9.68 BRCA1
6 Decreased viability GR00342-S-1 9.68 FLT4
7 Decreased viability GR00342-S-2 9.68 FLT4
8 Decreased viability GR00342-S-3 9.68 FLT4
9 Decreased viability GR00402-S-2 9.68 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
10 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
12 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT1
2 cellular MP:0005384 10.49 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
3 homeostasis/metabolism MP:0005376 10.49 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
4 growth/size/body region MP:0005378 10.48 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
5 behavior/neurological MP:0005386 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6 mortality/aging MP:0010768 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
7 embryo MP:0005380 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
8 immune system MP:0005387 10.42 BRCA1 BRCA2 ESR1 FGFR1 FLT1 FLT4
9 digestive/alimentary MP:0005381 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
10 hematopoietic system MP:0005397 10.38 BRCA1 BRCA2 ESR1 FGF2 FGFR1 FLT1
11 integument MP:0010771 10.38 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
12 endocrine/exocrine gland MP:0005379 10.36 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
13 muscle MP:0005369 10.32 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT1
14 nervous system MP:0003631 10.31 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
15 neoplasm MP:0002006 10.27 BRCA1 BRCA2 ERBB2 ESR1 FGF2 IL6
16 limbs/digits/tail MP:0005371 10.26 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6ST
17 normal MP:0002873 10.24 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
18 craniofacial MP:0005382 10.21 ERBB2 FGFR1 KDR KRT5 MET MMP2
19 liver/biliary system MP:0005370 10.11 ESR1 FLT4 IL6 IL6ST KDR MET
20 no phenotypic analysis MP:0003012 10.1 ESR1 FGFR1 FLT4 KDR KRT19 KRT5
21 reproductive system MP:0005389 10.1 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
22 adipose tissue MP:0005375 10.03 BRCA1 ESR1 FLT4 IL6 TP53
23 renal/urinary system MP:0005367 9.87 BRCA1 ESR1 FGFR1 IL6 MET TP53
24 respiratory system MP:0005388 9.81 BRCA1 ERBB2 ESR1 IL6 KDR MET
25 skeleton MP:0005390 9.8 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
26 vision/eye MP:0005391 9.32 FGF2 FGFR1 FLT1 IL6 IL6ST KDR

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
2
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
3
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
4
Metformin Approved Phase 3 657-24-9 4091 14219
5
Pembrolizumab Approved Phase 3 1374853-91-4
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
8 Peripheral Nervous System Agents Phase 3
9 Anti-Inflammatory Agents Phase 3
10 Neurotransmitter Agents Phase 3
11 Contraceptives, Oral Phase 3
12 Contraceptive Agents Phase 3
13 Contraceptive Agents, Male Phase 3
14
Medroxyprogesterone Phase 3 520-85-4 10631
15 Parasympatholytics Phase 3
16 Cholinergic Agents Phase 3
17 Muscarinic Antagonists Phase 3
18 Mandelic Acids Phase 3
19 Renal Agents Phase 3
20 Cholinergic Antagonists Phase 3
21 Autonomic Agents Phase 3
22 Anti-Infective Agents, Urinary Phase 3
23 Anti-Infective Agents Phase 3
24 Anti-Allergic Agents Phase 3
25 Dermatologic Agents Phase 3
26 Hypoglycemic Agents Phase 3
27 Immunologic Factors Phase 3
28 Antibodies Phase 3
29 Immunoglobulins Phase 3
30 Antineoplastic Agents, Immunological Phase 3
31 Antibodies, Monoclonal Phase 3
32 Progestins Phase 3
33
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
34
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
35
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
36
Epirubicin Approved Phase 2 56420-45-2 41867
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
39
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
40
Ethanol Approved Phase 2 64-17-5 702
41
Simvastatin Approved Phase 2 79902-63-9 54454
42
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
43
Polyestradiol phosphate Approved Phase 2 28014-46-2
44
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
45
Iodine Approved, Investigational Phase 2 7553-56-2 807
46
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
49
St. John's Wort Approved, Investigational, Nutraceutical Phase 2 84082-80-4
50
Sulforaphane Investigational Phase 2 4478-93-7, 142825-10-3 5350

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
2 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
3 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
4 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
5 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
6 A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
7 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
8 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
9 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Recruiting NCT02954874 Phase 3
10 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride
11 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
12 A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS Active, not recruiting NCT00907868 Phase 3
13 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
14 International Breast Cancer Intervention Study II (IBIS-II) (DCIS) Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
15 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
16 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
17 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
18 A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women Withdrawn NCT00324714 Phase 3 risedronate sodium
19 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
20 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
21 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
22 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
23 Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis Completed NCT02556632 Phase 2 Curcumin-based Gel
24 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
25 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
26 Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen Completed NCT00031720 Phase 2 Tamoxifen
27 Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population Completed NCT00764322 Phase 2 tamoxifen citrate
28 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Completed NCT02137252 Phase 2 Naltrexone;Sugar Pill
29 Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy Completed NCT00244959 Phase 2 anastrozole
30 A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole Completed NCT00354640 Phase 2 anastrozole;simvastatin
31 A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels Completed NCT00090857 Phase 2 Letrozole
32 Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates Completed NCT00054301 Phase 2
33 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
34 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
35 A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
36 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
37 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
38 NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer Recruiting NCT03345420 Phase 2
39 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
40 Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast Recruiting NCT02993159 Phase 2 Afimoxifene;Tamoxifen Citrate
41 Utilization of Telehealth to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients Recruiting NCT04054557 Phase 2
42 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
43 A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
44 Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial Recruiting NCT01688388 Phase 1, Phase 2
45 Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial Recruiting NCT02598557 Phase 2 Exemestane
46 Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial Recruiting NCT00909909 Phase 2
47 TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial) Active, not recruiting NCT02526498 Phase 2
48 A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma Active, not recruiting NCT01082211 Phase 2
49 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC) Active, not recruiting NCT01556243 Phase 2
50 VADIS Trial: Phase II Trial of Nelipepimut-S Peptide Vaccine in Women With DCIS of the Breast Active, not recruiting NCT02636582 Phase 2 Nelipepimut-S Plus GM-CSF Vaccine

Search NIH Clinical Center for Breast Carcinoma in Situ

Cochrane evidence based reviews: breast carcinoma in situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

41
Breast, Testes, Lymph Node, Skin, Bone, Endothelial, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

19
Breast

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show top 50) (show all 157)
# Title Authors PMID Year
1
MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. 38
30259272 2019
2
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. 38
30875106 2019
3
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. 38
30816935 2019
4
Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer. 38
31417875 2019
5
Clinical presentation of ductal carcinoma in situ of breast with intraluminal crystalloids: Radiologic-histologic correlation. 38
30241034 2018
6
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. 38
30025999 2018
7
Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. 38
30037866 2018
8
Single-cell heterogeneity in ductal carcinoma in situ of breast. 38
29148540 2018
9
Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention Trials. 38
29489512 2018
10
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. 38
29513252 2018
11
Expression of periostin in breast cancer cells. 38
28902360 2017
12
Risk of death from breast cancer after treatment for ductal carcinoma in situ. 38
28832961 2017
13
Non-calcified ductal carcinoma in situ of the breast: comparison of diagnostic accuracy of digital breast tomosynthesis, digital mammography, and ultrasonography. 38
27837442 2017
14
Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. 38
28394473 2017
15
Loss of Tpm4.1 leads to disruption of cell-cell adhesions and invasive behavior in breast epithelial cells via increased Rac1 signaling. 38
28431393 2017
16
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. 38
27639877 2017
17
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study. 38
28190250 2017
18
Ductal carcinoma in situ of breast: detection and treatment pattern in Hong Kong. 38
27779099 2017
19
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. 38
28894698 2017
20
Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. 38
28086982 2017
21
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. 38
27926499 2017
22
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. 38
28286675 2017
23
[Chinese expert consensus on the diagnosis and treatment of breast carcinoma in situ]. 38
27998472 2016
24
Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. 38
26876209 2016
25
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study. 38
27648168 2016
26
Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. 38
27589390 2016
27
Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. 38
27644608 2016
28
Cancer statistics: Breast cancer in situ. 38
26431342 2015
29
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. 38
26276354 2015
30
Basal cytokeratin phenotypes of myoepithelial cells indicates the origin of ductal carcinomas in situ of the breast. 38
26336082 2015
31
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. 38
26062614 2015
32
Context-Dependent Function of Myoepithelial Cells in Breast Morphogenesis and Neoplasia. 38
28680803 2015
33
Acoustic radiation force impulse elastography for differentiation of malignant and benign breast lesions: a meta-analysis. 38
26131049 2015
34
A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer. 38
25410791 2014
35
Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma. 38
25109497 2014
36
Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma. 38
25119601 2014
37
The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. 38
25203208 2014
38
Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens. 38
24678687 2014
39
[The relationship between passive smoking, breast cancer risk and n-acetyltransferase 2 (NAT2)]. 38
24791559 2014
40
[Sentinel lymph node metastasis in patients with ductal breast carcinoma in situ]. 38
25312311 2014
41
High-resolution 3D micro-CT imaging of breast microcalcifications: a preliminary analysis. 38
24393444 2014
42
Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. 38
24966968 2014
43
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. 38
23208501 2013
44
Comparison of two breast carcinomas: ductal carcinoma in situ and lobular carcinoma in situ. 38
24147320 2013
45
[Expression Wnt2 in breast cancer tissues and sera of the patients]. 38
23746249 2013
46
Prospective study on physical activity and risk of in situ breast cancer. 38
23074288 2012
47
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. 38
22595929 2012
48
Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. 38
22317899 2012
49
MRI morphological classification of ductal carcinoma in situ (DCIS) correlating with different biological behavior. 38
21296513 2012
50
Postmenopausal hormone therapy is associated with in situ breast cancer risk. 38
23098493 2012

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.24 VEGFC VEGFA TP53 PGR MET KDR
2
Show member pathways
13.95 VEGFC TP53 MMP2 MET KDR IL6ST
3
Show member pathways
13.93 VEGFC VEGFA TP53 MET KDR IL6
4
Show member pathways
13.76 VEGFC VEGFA TP53 MMP2 MET KDR
5
Show member pathways
13.74 TP53 MET KDR IL6ST IL6 FLT4
6
Show member pathways
13.62 VEGFC MET KDR IL6 FLT4 FLT1
7
Show member pathways
13.61 VEGFC VEGFA TP53 MET KDR IL6
8
Show member pathways
13.57 VEGFA MMP2 MET KRT5 KRT19 KDR
9
Show member pathways
13.5 VEGFC TP53 MET KDR IL6 FLT4
10
Show member pathways
13.44 VEGFA TP53 MMP2 MET IL6ST IL6
11
Show member pathways
13.41 VEGFC MET KDR IL6 FLT4 FLT1
12
Show member pathways
13.38 VEGFC MET KDR IL6 FLT4 FLT1
13
Show member pathways
13.37 VEGFC VEGFA MET KDR IL6 FLT4
14
Show member pathways
13.17 VEGFC TP53 MET KDR IL6 FLT4
15
Show member pathways
13.15 VEGFC MET KDR IL6 FLT4 FLT1
16
Show member pathways
13.09 VEGFC VEGFA PGR MMP2 KRT19 ESR1
17
Show member pathways
13.05 MET KDR FLT4 FLT1 FGFR1 ERBB2
18
Show member pathways
13 VEGFC VEGFA MET KDR FLT4 FLT1
19
Show member pathways
12.91 VEGFA TP53 FGFR1 ERBB2 BRCA2
20
Show member pathways
12.85 VEGFC VEGFA MET KDR FLT4 FLT1
21 12.82 VEGFC VEGFA TP53 MET KDR FLT4
22
Show member pathways
12.81 VEGFC MET KDR IL6 FLT4 FLT1
23
Show member pathways
12.79 TP53 MET FGFR1 FGF2 ERBB2
24
Show member pathways
12.77 TP53 PGR MET FLT4 FGFR1 FGF2
25
Show member pathways
12.77 VEGFC VEGFA TP53 MET KDR IL6
26
Show member pathways
12.68 VEGFC VEGFA KDR FLT4 FLT1
27
Show member pathways
12.66 TP53 MMP2 IL6 FGF2 ERBB2
28
Show member pathways
12.63 VEGFA TP53 MET ERBB2
29
Show member pathways
12.63 TP53 MET KDR FLT4 FLT1 FGFR1
30 12.6 VEGFA TP53 MET ERBB2 BRCA1
31
Show member pathways
12.58 TP53 MET KDR FLT4 FLT1 FGFR1
32
Show member pathways
12.53 VEGFC VEGFA MET KDR FLT4 FLT1
33
Show member pathways
12.52 VEGFC MET KDR IL6 FLT4 FLT1
34
Show member pathways
12.49 VEGFC VEGFA KDR FLT4 FLT1
35
Show member pathways
12.45 VEGFA KDR ESR1 BRCA1
36
Show member pathways
12.39 VEGFC TP53 MET KDR IL6 FLT4
37
Show member pathways
12.37 VEGFC VEGFA KDR FLT1 FGFR1 FGF2
38
Show member pathways
12.36 TP53 IL6 FGFR1 FGF2
39
Show member pathways
12.34 TP53 MET KDR IL6ST FLT4 FLT1
40
Show member pathways
12.33 VEGFA TP53 MMP2 MET KDR IL6
41 12.31 TP53 MET IL6 FLT1
42 12.26 VEGFA TP53 ESR1 BRCA2 BRCA1
43 12.25 VEGFA TP53 MMP2 IL6
44 12.23 TP53 MET KDR IL6ST FLT4 FLT1
45 12.22 VEGFA MET KRT19 KDR IL6 FGF2
46 12.22 VEGFA TP53 MMP2 MET KDR FGFR1
47
Show member pathways
12.2 VEGFC MET KDR IL6 FLT4 FLT1
48
Show member pathways
12.19 MMP2 IL6ST IL6 ERBB2
49 12.17 VEGFA TP53 MMP2 KDR
50 12.17 VEGFA TP53 MMP2 KDR FLT1

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFC VEGFA MMP2 MET KDR IL6ST
2 receptor complex GO:0043235 9.17 MET KDR IL6ST FLT4 FLT1 FGFR1
3 interleukin-6 receptor complex GO:0005896 9.16 IL6ST IL6
4 membrane GO:0016020 10.2 VEGFC VEGFA TP53 PGR MMP2 MET
5 plasma membrane GO:0005886 10.11 MMP2 MET KRT19 KDR IL6ST FLT4
6 cytoplasm GO:0005737 10.07 VEGFA TP53 PGR MMP2 KRT5 KDR

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.97 VEGFC VEGFA KDR FLT1 FGF2 BRCA1
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.96 MET KDR FLT4 FLT1 ERBB2
3 cell differentiation GO:0030154 9.95 VEGFC VEGFA TP53 KDR FLT1 FGF2
4 positive regulation of endothelial cell proliferation GO:0001938 9.93 VEGFC VEGFA KDR FLT4 FGF2
5 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.92 VEGFC VEGFA KDR FLT4 FLT1
6 positive regulation of MAP kinase activity GO:0043406 9.91 VEGFA FLT1 FGFR1 FGF2 ERBB2
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 VEGFA TP53 IL6
8 positive chemotaxis GO:0050918 9.88 VEGFC VEGFA MET FGF2
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 KDR FLT1 FGFR1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 VEGFA IL6ST IL6
11 response to estrogen GO:0043627 9.87 KRT19 ESR1 BRCA1
12 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.87 VEGFA KDR FLT4 FLT1
13 positive regulation of epithelial cell proliferation GO:0050679 9.86 VEGFC VEGFA ERBB2
14 positive regulation of endothelial cell migration GO:0010595 9.85 VEGFA KDR FLT4
15 positive regulation of cell division GO:0051781 9.84 VEGFC VEGFA FGF2
16 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.83 VEGFA KDR FGF2
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 VEGFC VEGFA KDR FGFR1 FGF2
18 regulation of angiogenesis GO:0045765 9.82 IL6 FGF2 ERBB2
19 sprouting angiogenesis GO:0002040 9.82 VEGFC VEGFA FLT4
20 blood vessel morphogenesis GO:0048514 9.81 FLT4 FLT1 FGFR1
21 positive regulation of vascular endothelial growth factor production GO:0010575 9.81 IL6ST FLT4 BRCA1
22 peptidyl-tyrosine phosphorylation GO:0018108 9.8 MET KDR FLT4 FLT1 FGFR1 ERBB2
23 cell migration involved in sprouting angiogenesis GO:0002042 9.79 VEGFA KDR FGF2
24 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.77 TP53 BRCA2 BRCA1
25 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 KDR FLT4 FLT1 FGF2
26 angiogenesis GO:0001525 9.76 VEGFC VEGFA MMP2 KDR FLT4 FLT1
27 positive regulation of MAPK cascade GO:0043410 9.73 KDR IL6 FLT4 FLT1 FGFR1 ERBB2
28 chordate embryonic development GO:0043009 9.72 FGFR1 BRCA2 BRCA1
29 induction of positive chemotaxis GO:0050930 9.71 VEGFC VEGFA
30 positive regulation of positive chemotaxis GO:0050927 9.71 VEGFA KDR
31 positive regulation of acute inflammatory response GO:0002675 9.71 IL6ST IL6
32 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.71 TP53 ESR1
33 positive regulation of phospholipase C activity GO:0010863 9.71 FLT1 FGFR1 FGF2 ESR1
34 positive regulation of endothelial cell chemotaxis GO:2001028 9.7 MET FGF2
35 positive regulation of protein kinase C signaling GO:0090037 9.69 VEGFA FLT4
36 paracrine signaling GO:0038001 9.68 PGR FGF2
37 positive regulation of mast cell chemotaxis GO:0060754 9.68 VEGFC VEGFA
38 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.67 VEGFA KDR
39 positive regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000546 9.65 FGFR1 FGF2
40 negative regulation of apoptotic process GO:0043066 9.43 VEGFA TP53 KDR IL6ST IL6 FLT4
41 vascular endothelial growth factor signaling pathway GO:0038084 9.02 VEGFC VEGFA KDR FLT4 FLT1
42 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 VEGFA TP53 PGR MET IL6 FGF2
43 phosphorylation GO:0016310 10.15 MET KDR FLT4 FLT1 FGFR1 ERBB2
44 protein phosphorylation GO:0006468 10.14 MET KDR FLT4 FLT1 FGFR1 ERBB2
45 positive regulation of transcription, DNA-templated GO:0045893 10.14 TP53 IL6 FGF2 ESR1 BRCA2 BRCA1
46 positive regulation of gene expression GO:0010628 10.08 VEGFA TP53 IL6 ERBB2 BRCA1
47 cytokine-mediated signaling pathway GO:0019221 10.06 VEGFA TP53 MMP2 IL6ST IL6 FGF2
48 negative regulation of gene expression GO:0010629 10.03 VEGFA PGR KDR FGFR1 ESR1
49 positive regulation of cell proliferation GO:0008284 10.02 VEGFC VEGFA KDR IL6ST IL6 FLT4
50 positive regulation of protein phosphorylation GO:0001934 10.01 VEGFC VEGFA KDR FLT4 ERBB2

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.96 VEGFA TP53 PGR MET KDR FGFR1
2 protein kinase activity GO:0004672 9.93 MET KDR FLT4 FLT1 FGFR1 ERBB2
3 growth factor activity GO:0008083 9.81 VEGFC VEGFA IL6 FGF2
4 protein phosphatase binding GO:0019903 9.73 TP53 MET FLT4 ERBB2
5 chemoattractant activity GO:0042056 9.65 VEGFC VEGFA FGF2
6 vascular endothelial growth factor-activated receptor activity GO:0005021 9.58 KDR FLT4 FLT1
7 interleukin-6 receptor binding GO:0005138 9.55 IL6ST IL6
8 growth factor binding GO:0019838 9.55 KDR IL6ST FLT4 FLT1 ERBB2
9 receptor-receptor interaction GO:0090722 9.49 FGFR1 FGF2
10 protein tyrosine kinase activity GO:0004713 9.43 MET KDR FLT4 FLT1 FGFR1 ERBB2
11 vascular endothelial growth factor receptor 3 binding GO:0043185 9.22 VEGFC
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 MET KDR FLT4 FLT1 FGFR1 ERBB2
13 transmembrane signaling receptor activity GO:0004888 9.07 ERBB2
14 protein binding GO:0005515 10.3 VEGFC VEGFA TP53 PGR MMP2 MET
15 kinase activity GO:0016301 10.01 MET KDR FLT4 FLT1 FGFR1 ERBB2

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....